U.S. Markets close in 4 hrs 26 mins

Bob Azelby awaits approval of Alder’s migraine drug

Tony Lystra
Bob Azelby awaits approval of Alder’s migraine drug

In a significant milestone for Alder, the U.S. Food and Drug Administration agreed on April 22 to review the biologics license application for the company’s flagship migraine drug, the company discovered and developed over the last decade. FDA approval could come as early as the first quarter of 2020.